Kyle Kline - 08 Jan 2026 Form 4 Insider Report for GLOBUS MEDICAL INC (GMED)

Signature
/s/ Kelly G. Huller, Attorney-in-Fact
Issuer symbol
GMED
Transactions as of
08 Jan 2026
Net transactions value
-$176,933
Form type
4
Filing time
12 Jan 2026, 17:40:20 UTC
Previous filing
13 Jan 2026
Next filing
23 Jan 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kline Kyle Senior Vice President, CFO VALLEY FORGE BUSINESS CENTER, 2560 GENERAL ARMISTEAD AVENUE, AUDUBON /s/ Kelly G. Huller, Attorney-in-Fact 12 Jan 2026 0002080625

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GMED Class A Common Stock Options Exercise $186,421 +3,594 $51.87 3,594 08 Jan 2026 Direct
transaction GMED Class A Common Stock Sale $363,353 -3,594 -100% $101.10 0 08 Jan 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GMED Stock Option (Right to Buy Class A Common Stock) Options Exercise $0 -3,594 -48% $0.000000 3,906 08 Jan 2026 Class A Common Stock 3,594 $51.87 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This sale was effectuated pursuant to a Rule 10b5-1 trading plan dated August 25, 2025 executed by the reporting person.
F2 These options were granted on March 14, 2024, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2025, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.